Advertisement


Solange Peters, MD, PhD, and Mary Gospodarowicz, MD, on Mentoring Women in Oncology: An International Perspective

2017 ASCO Annual Meeting

Advertisement

Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD, of Princess Margaret Hospital, a recipient of the 2017 Women Who Conquer Cancer Mentorship Award.



Related Videos

Hepatobiliary Cancer

Ann-Lii Cheng, MD, PhD, on Hepatocellular Carcinoma: Trial Results on Lenvatinib vs Sorafenib

Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Breast Cancer
Survivorship

Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)

Lymphoma

Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous vs matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure. (Abstracts 7506, 7508)

Hematologic Malignancies

David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)

Advertisement

Advertisement




Advertisement